Aldurazyme Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Aldurazyme market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as the expansion of personalized medicine, increased awareness of rare diseases, a higher use of enzyme replacement therapy, greater insurance coverage, and the adoption of novel drug delivery methods.

Market growth during the forecast period is expected to be driven by factors such as the increasing identification of genetic disorders, a rising awareness of enzyme deficiencies, a growth in clinical trials, higher healthcare spending, and a growing number of healthcare professionals. Major trends during the forecast period include advancements in technology, the adoption of gene therapies, personalized medicine, combination therapies, and the integration of artificial intelligence.

The growth in the number of clinical trials is expected to drive the expansion of the aldurazyme market. Clinical trials are research studies designed to assess the safety, efficacy, and potential side effects of new treatments, drugs, or medical devices in human participants. The rise in clinical trials is fueled by the increasing demand for innovative therapies, advancements in medical research, and a greater focus on personalized healthcare. These trials are crucial for aldurazyme, as they provide essential data on its safety, effectiveness, and long-term benefits for patients with mucopolysaccharidosis type I, helping to improve treatment protocols and broaden its clinical applications. For example, in November 2023, the Association of the British Pharmaceutical Industry reported a slight 4.3% increase in the number of industry clinical trials initiated in the UK, rising from 394 trials in 2021 to 411 in 2022. Additionally, participant recruitment for these trials grew by 15%, with 5,366 new participants, bringing the total to 42,088 in 2022/23. Thus, the growth in clinical trials is contributing to the expansion of the aldurazyme market.

The rising healthcare expenditure is also expected to drive the growth of the aldurazyme market. Healthcare expenditure encompasses the total financial resources allocated to healthcare services, including medical treatments, infrastructure, and administrative costs. The increase in healthcare spending is primarily driven by factors such as aging populations, advancements in medical technology, and the higher prevalence of chronic diseases. As healthcare expenditure rises, it increases funding and access to specialized treatments such as Aldurazyme, thus boosting demand for its use in managing lysosomal storage disorders. For instance, in May 2024, the Office for National Statistics reported a 5.6% increase in healthcare expenditure from 2022 to 2023, compared to a growth of just 0.9% in 2022. Government spending, which is the main source of healthcare funding in the UK, amounted to $302 billion in 2023, representing 81.9% of the country’s total healthcare expenditure. Therefore, the increase in healthcare spending is driving the growth of the aldurazyme market.

In November 2023, Elliott Investment Management, a US-based investment firm, acquired a $1 billion stake in BioMarin. This acquisition is expected to lead to changes at BioMarin, with Elliott, an activist investor, engaging in discussions about the company’s future and potential operational improvements. BioMarin Pharmaceutical Inc., based in the US, is the manufacturer of aldurazyme.

The key company operating in the aldurazyme market are BioMarin Pharmaceuticals Inc. and Sanofi S.A.

North America was the largest region in the aldurazyme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in aldurazyme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the aldurazyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Aldurazyme is a prescription medication categorized as an enzyme replacement therapy (ERT). It is used to treat mucopolysaccharidosis type I (MPS I), a rare genetic disorder caused by a deficiency of the enzyme α-L-iduronidase. This enzyme is essential for breaking down glycosaminoglycans (GAGs), substances that accumulate in the body and lead to various health complications. Aldurazyme provides a synthetic version of the missing enzyme, helping to reduce GAG buildup in tissues and alleviate symptoms associated with the disorder.

Aldurazyme is indicated for conditions such as Hurler syndrome, Hurler-Scheie syndrome, and Scheie syndrome. Hurler syndrome, or mucopolysaccharidosis type I (MPS I), is a rare genetic condition resulting from a deficiency of the enzyme alpha-L-iduronidase, causing the buildup of glycosaminoglycans in the body. The medication is distributed through multiple channels, including hospitals, clinics, and retail pharmacies, and is used by patients across pediatric, adult, and geriatric populations.

The aldurazyme market research report is one of a series of new reports that provides aldurazyme market statistics, including aldurazyme industry global market size, regional shares, competitors with a aldurazyme market share, detailed aldurazyme market segments, market trends and opportunities, and any further data you may need to thrive in the aldurazyme industry. This aldurazyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aldurazyme market consists of sales of rare disease medications, vaccines, and endocrinology products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.